Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up


1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan and University of Milan, Milan, Italy; 2Klinikum Stuttgart-Olghospital, Stuttgart, Germany; 3Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisbon, Portugal; 4Turku University Hospital (Turun Yliopistollinen Keskussairaala), Turku, Finland; 5University Hospital Essen, Essen, Germany; 6Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy; 7Institut Cune, Paris, France; 8Biolinics Thessaloniki, Thessaloniki, Greece; 9Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 10Royal Manchester Children’s Hospital, Manchester, UK; 11Virgen del Rocio University Hospital, Seville, Spain; 12Gustave Roussy Cancer Campus, Villejuif, France; 13Centro di Riferimento Oncologico di Aviano, Aviano, Italy; 14Laboratorio di Biomedicine of Sevilla (IBIS), Virgen del Rocio University Hospital/CSC/University of Sevilla/CIBERONC, Seville, Spain; 15Ospedale Regionale di Treviso “S.Maria di Ca Fancello”, Treviso, Italy; 16Integrated Unit ICD Hospital, HUB, Barcelona, Spain; 17Sarcoma Unit, University College London Hospitals NHS Trust, London, UK; 18Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands; 19Ghent University Hospital (Pediatric Hematology-Oncology & Stem Cell Transplantation), Ghent, Belgium; 20University Hospital Lund, Lund, Sweden; 21Pediatric Oncology and Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, University of Turin, Turin, Italy; 22N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation; 23Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 24Istituto Ortopedico Rizzoli, Bologna; 25Medical University of Bialystok, Bialystok, Poland; 26Department of Oncology, University of Turin Children’s Hospital, Turin, Italy; 27University Hospital Essen, Essen, Germany; 28Department of Medicine III, University Hospital Ludwig-Maximilians-University Munich, Munich, Germany; 29Helsinki University Central Hospital (HUCH), Helsinki, Finland; 30Royal Marsden Hospital, London, UK; 31The Institute of Cancer Research, London, UK; 32Department of Radiation Therapy, The Netherlands Cancer Institute, Amsterdam and Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands; 33Oxford University Hospitals NHS Foundation Trust, Oxford, UK; 34Mannheim University Medical Center, Mannheim, Germany; 35Department of Medicine III, University Hospital Ludwig-Maximilians-University Munich, Munich, Germany; 36Helsinki University Central Hospital (HUCH), Helsinki, Finland; 37Royal Marsden Hospital, London, UK; 38The Institute of Cancer Research, London, UK; 39University Medical Center Groningen, Groningen, The Netherlands; 40Radboud University Medical Centre, Nijmegen, The Netherlands; 41St. Anna Children’s Hospital & Children’s Cancer Research Institute, Medical University Vienna, Vienna, Austria; 42University Hospital Motol, Prague; 43Masaryk Memorial Cancer Institute, Brno, Czech Republic; 44Maria Skłodowska-Curie Institute-Oncology Centre, Warsaw, Poland; 45Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel; 46Medical Oncology University Hospital of Lausanne, Lausanne, Switzerland; 47Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK; 48Azienda Ospedaliera Universitaria Polliclinico S Orsola-Malpighi Università di Bologna, Bologna, Italy; 49Fundacio de Gestió Sanitaria de L’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 50Helios Klinikum Berlin Schöneberg, Berlin, Germany; 51CRRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Sheffield, UK; 52Aarhus University Hospital, Aarhus, Finland; 53Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; 54Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 55Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; 56Institute of Oncology of Ljubljana, Ljubljana, Slovenia; 57Netherlands Cancer Institute Antwo van Leeuwenhoek, Amsterdam, The Netherlands; 58Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, Germany; 59Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 60Centre Leon Bernard and UCLB, Lyon, France

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org

†Approved by the ESMO Guidelines Committee, PaedCan and EURACAN: August 2018.

‡Contributed equally.
Incidence and epidemiology

Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCAR case registry. Different bone tumour subtypes have distinct patterns of incidence, and each has no more than 0.3 incident cases per 100,000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age [2–4].

OS is the first primary cancer of bone (incidence: 0.3 per 100,000 per year). The incidence is higher in adolescents (0.8–1.1 per 100,000 per year at age 15–19 years) [2–3]. The male to female ratio is 1.4:1. Most OSs of younger patients arise in an extremity, while the proportion of axial tumour sites increases with age. Risk factors for the occurrence of OS include previous radiotherapy (RT), Paget disease of bone and germline genetic abnormalities associated with Li–Fraumeni syndrome, Werner syndrome, Rothmund–Thomson syndrome, Bloom syndrome and hereditary retinoblastoma [5].

CS is the most frequent bone sarcoma of adulthood. The incidence is ~0.2 per 100,000 per year, with a median age at diagnosis between 30 and 60 years. No gender predominance has been reported [2–4, 6].

ES is the third most common primary malignant bone tumour. It occurs most frequently in children and adolescents, but it is also seen in adults. Median age at diagnosis is 15 years and there is a male predominance (1.5:1). In white Caucasians > 25 years old, ES has an incidence of 0.3 per 100,000 per year [1–4], and it is even rarer in the African and Asian population. The genetic basis for the difference between ethnic groups has been recently linked to a common genomic germline variant, which extends a microsatellite, thereby facilitating the binding of the EWSR1–FLI1 chimeric protein to the EGR2 gene locus, leading to higher expression of the transcription factor early growth response 2 (EGR2) and increased susceptibility to ES [7]. The most common primary sites are the extremity bones (50% of all cases), followed by pelvis, ribs and vertebra. However, any bone can potentially be affected and a soft tissue origin is also possible, especially in adults (30% of cases).

Chordomas are even rarer compared with other subtypes, with an incidence of ~0.5 per million per year [1–4].

High-grade spindle/pleomorphic sarcomas of bone are a heterogeneous group of primary malignant bone tumours that do not fulfill the histological criteria for a diagnosis of OS, CS or ES [8].

Giant cell tumour (GCT) of bone is a benign, locally aggressive and rarely metastatic intramedullary bone tumour composed of mononuclear cells and osteoclast-like multinucleated giant cells, with a variable and unpredictable potential for aggressive growth. It represents ~5% of primary bone tumours, with an incidence of approximately 1 per million per year [9].

Diagnosis and pathology/molecular biology

A general diagnostic strategy for bone sarcomas is shown in Figure 1. The medical history should focus on characteristic symptoms such as duration, intensity and timing of pain. The presence of persistent non-mechanical bone pain, predominantly at night, should prompt a radiological assessment. Swelling and functional impairment can be present if the tumour has progressed through the cortex and distended the periosteum, but they are often later signs. The differential diagnosis of a bone sarcoma includes osteomyelitis, benign tumours and bone metastases, all of which outnumber primary bone sarcomas [10–12]. The diagnosis can be strongly oriented by patient age. For patients < 5 years old, a destructive bone lesion could be interpreted predominantly as either metastatic neuroblastoma or Langerhans cell histiocytosis (LCH). For patients aged ≥ 5 years old, the likelihood of a primary bone sarcoma is higher. In adult patients, after 40 years of age, bone metastases and myeloma are the most common diagnoses [12].

Conventional radiograph in two planes is the first radiological investigation. When the diagnosis of malignancy cannot be excluded with certainty on radiographs, the next step should be magnetic resonance imaging (MRI) of the whole compartment with adjacent joints, which is regarded today as the best modality for local staging of extremity and pelvic tumours [13]. Computed tomography (CT) may provide additional information by allowing a better visualisation of calcifications, periosteal bone formation and cortical destruction. It is generally the imaging modality of choice of other primary sites.

All patients with a bone lesion that is likely to be a primary malignant bone tumour on a radiological basis should be referred to a bone sarcoma centre or to an institution belonging to a specialised sarcoma network [14–15]. Children and adolescents should be referred to centres which in addition provide age-specific expertise. The biopsy and the pathological diagnosis require expertise in the field and should be discussed in a multidisciplinary setting.

The biopsy of a suspected primary malignant bone tumour should be carried out at the reference centre for bone sarcomas, with a primary biopsy under the supervision of a surgical team who will carry out the definitive tumour resection or by a dedicated interventional radiologist [14–17]. In most patients, a core-needle biopsy, taken under imaging control, can be an appropriate alternative to open biopsy. Contamination of surrounding tissue should be minimised, and adequate multiple sampling of representative areas must always be provided. The biopsy approach and area of tumour to be sampled are pre-determined after multidisciplinary review of imaging. If osteomyelitis is a differential diagnosis, samples should be sent for microbiological culture. If required, an open biopsy should be carried out using a longitudinal incision. In aggressive and malignant tumours of bone, the biopsy tract and the channels through which drains have been placed must be considered to be potentially contaminated and must later be removed, together with the resection specimen, in an effort to minimise the risk of a local recurrence. Therefore, biopsy tracts should be clearly marked by means of a small incision or an ink tattoo to ensure that the location is recognised at the time of the definitive procedure. In case of spinal column involvement, laminectomy or decompression should be avoided unless necessary to relieve spinal cord compression, and tissue sampling must be carried out whenever a bone sarcoma is suspected.

Samples must be interpreted by an experienced bone sarcoma pathologist, in collaboration with the radiologist, and discussed in a multidisciplinary team. The request form should be
completed with all details that might be relevant for diagnosis, including patient’s age, the site of the tumour, radiological findings, presence of multiple lesions, family history and preoperative treatments for surgical specimens.

With the increasing capability for accurate molecular diagnosis and next-generation sequencing (NGS) technologies, samples should be quickly submitted for pathological assessment. The collection of fresh frozen tissue is strongly encouraged, to enable molecular diagnostics. As an alternative, decalcification in ethylene-diaminetetraacetic acid (EDTA) instead of methanoic acid can be considered. Tumour imprints (touch preparations) are used by some, but not all, expert institutions; they might be useful for tumour-specific translocation by fluorescent in situ hybridisation (FISH) in some institutions. Informed consent for tumour banking should be routinely sought as for all rare malignancies, enabling later analyses for research, depending on local regulations.

The nature of the bone specimen received for pathology reporting should be recorded, i.e. needle biopsy, curettage or excision (e.g. segmental resection, limb salvage amputation, or another complex resection, such as a hemipelvectomy). It is usually necessary to decalcify the bone tumour biopsy using specific standard operating procedures. The histological features of the tumour should be described and the tumour type (and subtype) specified according to the most recent version of the World Health Organization (WHO) classification [18, 19]. The results of relevant ancillary investigations (e.g. immunohistochemistry or molecular assessments) should be accurately recorded. Molecular diagnostic techniques currently available include FISH, reverse transcription-polymerase chain reaction (RT-PCR) and NGS technologies. Examples include translocation detection in ES and mesenchymal CS, isocitrate dehydrogenase (IDH1 and IDH2) mutations in conventional CS and MDM2 amplification in parosteal and intramedullary low-grade OS.

At the time of the resection of the primary tumour, the size of the tumour in the resected bone should be recorded (three-dimensional measurement in mm) [19, 20]. The pathology report should also describe the extent of local tumour spread, including involvement of specific anatomical soft tissue and bone compartments. It should be recorded whether the resection margins are either clear or infiltrated and the distance of tumour from the nearest resection margin measured (in mm). Photographs should be taken of the intact specimen and of the tumour slabs after sawing. A complete, representative slab of the tumour, usually in the longitudinal axis as guided by the radiological images, should be embedded in a grid manner for microscopy. This is especially relevant after neoadjuvant chemotherapy (ChT) to assess response. The tumour should be coded using Systematic Nomenclature of Medicine (SNOMED) or International Classification of Diseases for Oncology (ICD-O) codes.

Staging and risk assessment

All new cases of bone tumours should be formally discussed in a multidisciplinary team at a bone sarcoma reference centre with the radiologist, the pathologist, the surgeon, the radiation oncologist and the medical and/or paediatric oncologist. The output of the multidisciplinary discussion must be recorded.

Several staging systems for bone tumours are in use [20–22]. However, none of them is perfect or generally accepted. Tumour burden (volume) and the presence of detectable metastases are the two main factors that are taken into consideration in the clinical staging of these diseases. General staging should be carried out to assess the extent of distant disease, including bone scintigraphy, chest radiographs and CT [23]. Whole-body MRI and positron emission tomography (PET)-CT or PET-MRI are increasingly used for staging (including detection of ‘skip’ bone lesions) [24]. Additional appropriate imaging studies and biopsies can be taken from suspicious sites, as the exact staging of the disease has an impact on treatment and outcome.

No specific laboratory tests for the diagnosis of bone sarcoma are routinely available. Baseline serum analysis in ES and OS should include alkaline phosphatase (AP) and lactate dehydrogenase (LDH), given their proven prognostic value [25–27]. Prognostic features also include clinical presentation: a pathological fracture may lead to the dissemination of tumour cells into surrounding tissues and increase the risk of local recurrence. In cases of fracture, internal fixation is contraindicated as it disseminates the tumour further into both bone and soft tissues and increases the risk of local recurrence. External splintage is recommended.

ChT can result in renal, cardiac and auditory dysfunction. Before starting the treatment, baseline renal function testing, assessment of cardiac function [left ventricular ejection fraction (LVEF)] and audiogram (in the case of platinum derivatives) should be carried out. Sperm storage is recommended for male patients of reproductive age. For female patients, a fertility physician is routinely consulted about potential ovarian tissue sampling and cryopreservation in some but not all countries, reflecting a variability of healthcare policies across nations.

Treatment (locoregional and advanced disease)

Given the rarity of the disease and the complexity of management, the accepted standard for bone sarcomas is treatment at reference centres and/or within reference networks able to provide access to the full spectrum of care and age-specific expertise [III, A]. In these centres/networks, therapy is usually given within either the framework of prospective, often collaborative, clinical studies or established treatment protocols. In the case of high-grade OS, ES or pleomorphic sarcoma, following biopsy proven-diagnosis, primary ChT is generally recommended by expert centres.

Osteosarcoma

OS usually arises in the metaphysis of a long bone, most commonly around the knee in children and adolescents. Involvement of the axial skeleton and craniofacial bones is primarily observed in older patients. High-grade OS frequently metastasises, the lung being the most frequent metastatic site by far, followed by distant bones.
Conventional OS is always high-grade. Parosteal OSs are low-grade malignancies, although they may increase in size and invade the medulla of bone, and transform to high-grade sarcoma, whereas periosteal OS is an intermediate-grade chondroblastic OS, sometimes difficult to distinguish from high-grade surface OS. Adverse prognostic or predictive factors for conventional OS include detectable primary metastases, axial or proximal extremity tumour site, large tumour size, elevated serum AP or LDH and older age [III, B] [25, 26]. As mentioned above, staging should include local imaging studies, specifically plain radiographs and MRI of the whole affected extremity [III, A].

Curative treatment of high-grade OS consists of ChT and surgery [II, A]. Compared with surgery alone, multimodal ChT treatment of high-grade localised OS increases disease-free survival probability from 10%–20% to > 60%. In general, ChT is administered before and after surgery, although a formal proof that giving ChT preoperatively improves survival is lacking. The extent of histological response to preoperative ChT predicts survival [25–27].

Low-grade parosteal OSs are malignancies with a lower metastatic potential and should be treated by surgery alone [IV, B]. Although ChT has been used for periosteal OSs, no benefit for ChT was shown in retrospective analyses [28–30], and its use is not routinely recommended in this setting [IV, D].

Surgery should be carried out by a surgical team familiar with the wide range of surgical reconstructive options. Paediatric and adolescent patients need to be treated by surgeons with great experience in the field of paediatric bone tumours, including age-specific reconstruction challenges, such as the reconstruction of growing bones. The goal of surgery is to safely remove the tumour and yet preserve as much function as possible, striving to obtain microscopically clear surgical margins [27]. Most patients should be considered candidates for limb salvage. Either intrallesional or marginal margins increase the local relapse rate, which is associated with reduced overall survival. Thus, clear margins are the first goal of surgery [III, B]. Areas where there is suspicion of close margins should be marked on the surgical specimen sent to pathology.

Pathological fracture does not necessarily necessitate an amputation. In chemosensitive tumours, primary neoadjuvant ChT can be used with the expectation that it will allow the fracture haematoma to contract and allow subsequent resection of the tumour and the involved soft tissues [31].

Doxorubicin, cisplatin, high-dose methotrexate (HD-MTX) and ifosfamide have antitumour activity in OS [I, A] [32–35]. The MAP (doxorubicin/cisplatin/HD-MTX) regimen is most frequently used as the basis of treatment in children and young adult patients [30]; however, HD-MTX can be difficult to manage in adults. In patients aged > 40, regimens combining doxorubicin, cisplatin and ifosfamide without HD-MTX can also be used in these patients [III, B] [33–36]. These drugs should be administered with adequate supportive care by experienced paediatric oncologists or medical oncologists at reference institutions with appropriate infrastructure and a multidisciplinary treatment approach. Most current protocols include a period of preoperative ChT, to facilitate local surgical treatment and to allow the assessment of tumour response [32–41]. The EURAMOS 1 prospective trial aimed to establish whether PEGylated interferon alpha-2b (PEG-IFNα-2b), in addition to standard MAP ChT given postoperatively, could improve outcome in patients with good histological response to preoperative MAP. The results showed that many patients failed to start and complete interferon treatment, and there was no significant overall survival advantage [I, C] [34, 35]. The study also evaluated if altering postoperative ChT in poor responders to preoperative systemic therapy might have any impact on outcome, and, again, no survival benefit was proven. In the case of poor pathological response to the preoperative MAP regimen, the postoperative addition of ifosfamide and etoposide to MAP failed to improve the survival and increased the risk of secondary malignancy compared with those patients treated with the MAP regimen only [I, C] [36]. Whenever possible, patients with OS should receive ChT in the context of prospective studies.

Innate immune-modulation has been attempted in OS with other agents, in particular muramyl tripeptide. As described above, the use of interferon failed to show a survival advantage in patients with a good histological response to an MAP preoperative regimen. Muramyl tripeptide added to postoperative ChT was associated with a significant advantage in overall survival and a non-significant trend in event-free survival in one large randomised trial [II, C] [41]. Muramyl tripeptide has been approved in Europe for patients < 30 years of age with completely resected localised OS, but it is not reimbursed in all European countries. There is no consensus in the sarcoma community on the use of this drug, due to weaknesses in the data from the only trial currently available [41, 42]. Further studies are needed to identify any subgroup of patients who could benefit from immune modifying agents.

Dynamic MRI is reliable for evaluation of changes in tumour vascularity and to give additional information on tumour response to primary ChT [43, 44]. The value of diffusion MRI is currently under evaluation [44].

The multimodal treatment principles detailed above were generated in children, adolescents and young adults with high-grade central OS, but also relate to adults [III, B]. Adult patients may require tailored regimens, especially as far as HD-MTX is concerned, in particular for those aged > 40 years. Some studies have put a threshold of 25 years of age to remove HD-MTX from the induction regimen [45], while others included HD-MTX for older patients [46]. Doxorubicin plus cisplatin and/or ifosfamide are commonly used with age-adapted doses. Recently, the addition of zoledronic acid was tested in a randomised setting and failed to demonstrate an improvement in relapse-free or overall survival or histological response. Its use is, therefore, not recommended outside clinical trials [I, D].

In general, there is no indication for RT, but there are anatomical locations in which the possibility of complete surgical resection is limited. In these cases, after a multidisciplinary discussion, RT may be an option to try to extend the progression-free interval. This must be discussed in a multidisciplinary team beforehand with the patient, and it should be made clear at the time of surgery that the goal is not an R0 resection (excision whose margins are clear of tumour cells) [V, C]. New RT techniques (e.g. proton and carbon ion beam RT) should be considered, particularly for unresectable primary tumours [47].
Primary metastatic OS patients are treated with a curative intent following the same principles of non-metastatic OSs [48]. In fact, there are subsets of patients who can have a very similar prognosis to that of localised disease, provided surgical removal of all known metastatic deposits is achievable [III, B] [49]. Approximately 25% of all patients with primary metastatic OS and > 40% of those who achieve a complete surgical remission may become long-term survivors.

High-grade craniofacial OS should be treated the same way as high-grade OS of other locations, although prospective evidence is lacking due to the absence of selective clinical studies in this patient population [IV, B]. PET-CT scanning may be advantageous for response assessment [50]. RT, preferably within clinical studies, can be proposed when complete surgical therapy is not feasible [IV, B]. The value of proton/carbon ion beam RT in this setting is currently under study. Adjuvant RT follows the same recommendations as that for other sites (see above).

The management of recurrent OS needs to take into account the timing of recurrences/metastases, the number of metastases and the metastatic sites. CT scan can over- and under-estimate the number of pulmonary metastases, but the recent results have improved with spiral CT. The treatment of recurrent OS is primarily surgical in the case of isolated lung metastases. Complete removal of all metastases must be attempted [III, B], as the disease is otherwise almost universally fatal; more than a third of patients with a complete second surgical remission survive for > 5 years [51]. Even patients with subsequent recurrences may be cured as long as recurrences are resectable, and repeated thoracotomies are often warranted [51]. For lung metastases, stereotactic RT, radiofrequency ablation or cryotherapy might be used as alternative options in patients unfit for surgery [IV, B]. Some groups also consider radiofrequency ablation [52, 53] and stereotactic RT [54] to be potential alternative local treatment options for primary lung or bone metastases [52–54].

The role of second-line chemotherapy for recurrent OS is much less well defined. Treatment choice may take into account the prior disease-free interval, and often includes ifosfamide or cyclophosphamide, possibly in association with etoposide and/or carboplatin [III, B]; other active drugs and combinations include gemcitabine and docetaxel [IV, C], sorafenib [III, B] or regorafenib [II, B], as well as samarium ([153]Sm); the evidence for these drugs is limited and there are reimbursement constraints [55–60]. In the two largest reported series, the use of second-line ChT correlated with limited prolongation of survival in patients with inoperable metastatic recurrences, while a positive correlation in operable disease was observed in only one of the two [49, 50]. However, radiological responses and clinical benefit are commonly witnessed so that its use should be considered [IV, B].

RT may have a role in palliation. In general, despite second-line treatment, the prognosis of recurrent disease has remained poor, with a long-term post-relapse survival rate of < 20% [48, 49, 51].

Ewing sarcoma

ES is a small, blue, round cell tumour, periodic acid-Schiff (PAS) positive and CD99 (MIC2)-positive. All ESs are high-grade tumours. They can arise both from bone, soft tissues or visceral sites, displaying the same behaviour in principle.

The definitive diagnosis is made by biopsy, providing sufficient material for conventional histology, immunohistochemistry, molecular pathology and biobanking. Molecular biology studies have shown that almost all of these tumours share a common TET-ETS gene rearrangement involving the EWSR1 gene on chromosome 22 [61–64]. In most cases, this involves a reciprocal translocation t(11; 22)(q24; q12) [47], but t(21; 22)(q22; q12), and others may also occur [t(7; 22), t(17; 22) and t(2; 22)] [61–64]. In recent years, new small round cell sarcoma entities have been recognised, with novel translocations, among which BCL6 corepressor (BCOR)-rearranged sarcoma preferentially affects the bone. Other examples of recurrent molecular alterations found in these malignancies include EWS RNA binding protein 1—nuclear factor of activated T cells 2 (EWSR1-NFATC2), FUS RNA binding protein—nuclear factor of activated T cells 2 (FUS-NFATC2), capicua transcriptional repressor—forkhead box O4 (CIC-FOXO4) or capicua transcriptional repressor—double homeobox 4 (CIC-DUX4) translocations (see Table 1) [65–67].

Current investigations have shown that tumour biology and prognosis of these tumours, which are probably different nosological entities rather than molecular variants, actually differ from classical ES, making molecular testing mandatory. Currently, patients presenting with these variants are treated with Ewing-like regimens, although their best treatment and even their natural history are poorly known [65–67]. Inclusion in prospective registries is worthwhile [a European Reference Networks on adult rare solid cancers (EURACAN) sarcoma project is planned].

Although most ES tumours can be recognised with classical haematoxylin and eosin (H&E) stain, immunohistochemistry molecular confirmation is mandatory for the identification of the classical and distinct molecular subtypes as described above [III, A] [18, 62–67]. The laboratory should be enrolled in an external quality assurance programme. When frozen tissue is available, techniques that identify both fusion partners (i.e. RT-PCR or anchored, multiplex PCR-based, targeted NGS) are the techniques of choice. The latter can also be applied to non-decalcified or EDTA-decalcified, formalin-fixed paraffin-embedded (FFPE) tissue. FISH is a good choice when only FFPE tissue [or touch preparations (imprints)] are available. There are several commercial sources for EWSR1 break-apart probes. Assays using EWSR1 break-apart probes do not detect EWS-FLI1 fusions, but only EWSR1 rearrangements, which should not be a problem when interpreted in the appropriate clinical and pathological context. NGS should be considered when no typical translocation has been detected by conventional methods.

Bone marrow biopsies and aspirates (from sites distant to the primary or known metastatic lesions) may be considered in the staging, but several experts underline that there is a very low incidence of bone marrow metastases in localised disease if the PET scan is negative [68]. The added prognostic value of molecular positivity over light microscopic evaluation has not yet been proven [IV, C].

Between 20% and 25% of patients are diagnosed with metastatic disease [lung (10%); bone/bone marrow (10%); combinations or others (5%)] [69, 70]. Staging must be oriented to detect lung, bone and bone marrow metastases and should include biopsy in case of doubtful lesions. Multiple bone metastases confer a poorer outcome than lung/pleural metastases (< 20% compared...
with 20%–40% 5-year survival). Other known adverse prognostic factors are large tumour size or volume, elevated serum LDH levels, non-extremity localisation and age > 15 years. A poor histological response to preoperative ChT and incomplete or no surgery for local therapy are further adverse prognostic factors [71–75]. The molecular structure of the EWSR1 fusion transcripts has not been shown to be of prognostic value with current treatment protocols. Genomic analysis with the assessment of copy number variation has been shown to be of prognostic value [75, 76]. In addition, STAG2, TP53 and CDKN2A mutations confer poorer outcomes. With surgery or RT alone, i.e. without systemic treatments, 5-year survival was < 10%. With the currently recommended multimodal approaches including ChT, 5-year survival is ~ 60%–75% in localised and ~ 20%–40% in metastatic disease, respectively, depending on metastatic sites and burden (Figure 2).

Current trials employ 3–6 cycles of initial combination ChT after biopsy, followed by local therapy, and another 6–10 cycles of ChT, usually applied at 2- to 3-week intervals. Treatment duration is thus 10–12 months. Agents considered to be most active include doxorubicin, cyclophosphamide, ifosfamide, vincristine, dactinomycin and etoposide [77–81]. Almost all active protocols are based on five- to six-drug combinations of these substances [I, A]. Dose-dense regimens (with interval compression) were associated with a positive outcome in paediatric and adolescent (<18 years) patients in a prospective North American study [II, B] [82].

The use of high-dose ChT with escalated alkylating agent dose and blood stem cell rescue has attracted much attention in ES since the 1970s. Only recently have the results of randomised studies with busulfan and melphalan (BuMel) indicated that this approach results in a survival advantage for tightly defined and highly selected patients with poor response to induction ChT and/or tumour volume > 200 mL [I, B] [83, 84]. No such advantage was evident for patients presenting with pulmonary metastases [II, D] (Figure 2). ES is a radiosensitive tumour at lower doses than OS. The goal of local therapy for the primary tumour is to ensure that the entire volume of tissue involved at diagnosis is treated. Complete surgical excision, where feasible, is regarded as the best modality of local control, given the higher risk of local recurrence when RT is used as the sole treatment of the primary tumour. Surgery must involve excision of all tissues originally involved with tumour (not just the tissue that is left after ChT shrinkage) or be supplemented by RT. RT alone (in the range of 45–60 Gy, depending on location) should be applied if complete surgical excision is impossible. Postoperative RT should be given in cases of inadequate surgical margins and discussed when histological response in the surgical specimen was poor (i.e. > 10% viable tumour cells) [IV, B] [78]. The dose of postoperative RT is also 45–60 Gy, depending on margins, response and location. Intralional surgery must be avoided, as there is no benefit when compared with RT alone [78]. Change in the size of the soft tissue mass is easily evaluated on MRI and is a good predictor of tumour response [43, 44]. Sequential FDG-PET evaluation might be of additional value [85].

The treatment of adult patients follows the same principles as for children. However, tolerability of therapies in older patients needs to be taken into account when transferring treatment
Figure 2. General therapeutic strategy for the three most frequent bone sarcomas.

The treatment of primary bone sarcoma must be carried out in a bone sarcoma reference centre.

Depending on the chondrosarcoma subtype, treatment can be surgery, neoadjuvant and adjuvant ChT or RT. BuMel, busulfan and melphalan; ChT, chemotherapy; RT, radiotherapy.
High-grade spindle/pleomorphic sarcomas of bone

Pleomorphic sarcomas of bone comprise a diagnostically heterogeneous group of malignant tumours including undifferentiated pleomorphic sarcoma [8]. They arise in a similar age group to CS, but the skeletal distribution is more like OS. They typically present with pain and have a high incidence of fractures at presentation. They represent between 2% and 5% of primary bone malignancies. Males are more frequently affected than females. An association with pre-existing disease (Paget disease or bone infarct) or history of previous irradiation has been reported. It is not unusual for a spindle cell sarcoma to be found to be either a dedifferentiated CS or OS after examining further different sections of the resection. Therefore, the diagnosis should be established in a multidisciplinary setting and IDH mutation analysis should be considered when the radiological images suggest a CS.

Pleomorphic sarcomas typically present in older patients with a lytic lesion in bone. A metastatic lesion is often a differential diagnosis. Full staging and biopsy are required to reach a diagnosis. Pathological fractures are common and, as mentioned in the introduction, should not undergo internal fixation [91, 92]. Treatment strategies mimic those of OS, with ChT and complete en bloc resection including any soft tissue component. Their sensitivity to ChT is poorly known, and studies on specific histologies as currently defined (especially after reappraisal of histologies previously known as malignant fibrous histiocytoma (MFH)), are highly required. RT may be considered in inoperable lesions. A global effort to collect these cases would be helpful to establish diagnostic and prognostic criteria as well as recommended treatments, for the whole group as well as for the different histologies.

Chondrosarcoma

Most CSs arise as primary malignant tumours. The majority of CSs are low-grade, locally aggressive, non-metastasising tumours (atypical cartilaginous tumour/CS grade I), rather than high grade (grades II–III) [18, 93]. Grade I CSs can be labelled atypical cartilaginous tumours, as currently defined by the WHO 2013 classification, since they usually do not metastasise [18]. Grade I CSs may be treated with RT when located at critical sites such as the skull base. Most CSs arise centrally in the metaphyseal region of long bones, but they can also develop in flat bones such as pelvis, rib and scapula. High-grade CS frequently arises in the axial skeleton and long bones. CS can arise in pre-existing benign lesions such as enchondroma and osteochondroma [6]. In these circumstances, they are referred to as secondary central CSs and secondary peripheral CSs, respectively. The majority of CSs are of the conventional subtype, but rarer subtypes include mesenchymal and clear cell CS [33, 94]. In rare circumstances, conventional CSs can ‘dedifferentiate’ into a very high-grade tumour with a dismal prognosis: the so-called dedifferentiated CS [33, 94]. Most CSs are solitary, but they can occur as multiple lesions in syndromic patients with multiple osteochondromas and enchondromatosis [6].

Pain at the site of a cartilaginous lesion may be an indicator of malignancy. In the case of CS, a contrast-enhanced MRI can reveal high-grade areas. This provides a useful guide to the site of biopsy [95]. For large axial and pelvic CS, heterogeneity is common, and most lesions contain high-grade elements. The differentiation between benign enchondroma or osteochondroma and atypical cartilaginous tumour/CS grade I can be difficult, but can be aided by the use of dynamic contrast-enhanced MRI [96]. In the phalanges of the hands and feet, malignancy is extremely rare, but in the other long bones central cartilaginous lesions should be considered atypical cartilaginous tumour unless proven otherwise [94].

Inoperable, locally advanced and metastatic high-grade CSs have a poor prognosis [97]. Prognosis depends on histological grade. However, histological classification is subject to variability in interpretation, with grade II and III CSs often grouped together, even though there is a wide spectrum of outcome and heterogeneity of grade elements within tumours [74]. Also, grade I tumours (atypical cartilaginous tumours) are not necessarily curable in all cases, mainly due to problematic local recurrence or progression to high grade. Conversely, dedifferentiated CSs in particular are aggressive and frequently metastasise [33, 94].

Assessing the grade of CSs is difficult and discrepant diagnoses are common even among experts [93]. Atypical cartilaginous tumours are unlikely to metastasise, but may recur locally. Atypical cartilaginous tumours in the long bones of the limbs can be managed by curettage with or without local adjuvant (e.g. phenol, cement and cryotherapy), with a high chance of success.
Low-grade peripheral CSs (arising from osteochondromas) should be surgically excised, aiming to excise the tumour with a covering of normal tissue over it. Higher-grade CSs (grade II and III) and all CSs of the pelvis or axial skeleton should be surgically excised with wide margins [IV, B].

Evidence suggests that mesenchymal CS is more sensitive to ChT and therefore usually considered for adjuvant or neoadjuvant therapy [IV, C] [98, 99]. Most authors suggest a Ewing-type ChT regimen.

Dedifferentiated CS is often treated as a high-grade bone sarcoma, with systemic and local therapies that need to be adapted to patient’s age [V, C] [100, 101]. There is a very high risk of local recurrence following excision of dedifferentiated CS, particularly in the presence of a pathological fracture. If wide margins cannot be reliably achieved with limb salvage, amputation should be considered.

The role of RT in CS is limited, but may be appropriate in highly selected cases or for palliation. Excellent outcomes have been reported for skull base CSs with high-dose RT, including proton or carbon ion beam RT, achieving 80%–90% local control rates [102]. With regard to ChT, drugs active in sarcomas such as doxorubicin and ifosfamide may prove active in CS, especially in high-grade lesions [97]. The activity of gemcitabine in combination with docetaxel has been reported [103].

**Giant cell tumour of bone**

GCT of bone is a benign, locally aggressive and rarely metastatic tumour of the skeleton [9, 104]. GCT is classified in the intermediate category, as GCT can be aggressive and recur locally in up to 50% of cases [9, 104]. Soft tissue extension is significantly associated with the risk of local recurrence. Up to 5% of GCTs metastasise to the lungs, and transformation to a high-grade malignancy though debated, may occur in 1%–3% of patients. GCTs of bone contain mutations in the H3F3A gene (predominantly at the G34 position) which can be detected using mutation analysis or immunohistochemistry using mutation-specific antibodies [104, 105].

Treatment options include en bloc excision [IV, A] and intraluminal curettage with or without adjuvant in carefully selected cases. These have been assessed in a few prospective studies [106, 107]. Denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), known to be overexpressed in GCT, is standard treatment in unresectable or metastatic GCT [III, A] [107]. Its use in the neoadjuvant setting is debated and should be carried out exclusively in expert centres, and ideally within a clinical trial. There is increasing evidence that, if being used preoperatively and before curettage, surgery is best carried out after a few months of treatment, as otherwise extensive ossification may take place, making it difficult to define the extent of the lesion [V, C] [108]. It can also be used in unresectable disease and rare metastatic disease. In this setting, treatment interruption is usually followed by progression, so that treatment needs to be maintained [109]. Potential maxillary and skeletal side effects need to be monitored (osteonecrosis of the jaw, atypical fractures). The optimal schedule and duration of treatment with denosumab in surgically unsalvageable GCTs is still to be settled, and the possible long-term side effects are still largely unknown.

RT can provide a satisfactory local control in GCT (5-year control rate of 80%) [110]. However, the use of radiotherapy can be associated with a risk of GCT transformation into a high-grade sarcoma and can make surgical resection challenging if required. Therefore, the use of RT in GCTs should always be discussed in a multidisciplinary setting and be limited to cases in which surgery leads to unacceptable morbidity and denosumab is ineffective or contraindicated [IV, D].

**Chordoma**

Chordoma is a rare bone tumour (incidence: 0.1 per 100 000 per year) arising from the persistent notochordal elements in the spine (sacrum 50% and bones from the mobile spine 20%) and in the skull base (30%). Extraskeletal cases are extremely rare.

Median age is 60 years, but skull base presentations can also affect a younger population, including children and adolescents. Conventional chordoma is a low-grade, locally-invasive malignancy. Immunohistochemistry nuclear positivity for Brachyury is the diagnostic hallmark and its assessment is strongly recommended [111]. Dedifferentiated chordomas account for less than 5% of all cases and behave more aggressively than the conventional counterpart. T expression can be lost in dedifferentiated chordoma. Approximately 30% of patients with chordoma will develop metastases, usually late in the natural history of the disease, and mostly after local recurrence.

Because of the extreme rarity and the challenging sites of origin, chordoma management should be carried out at referral centres and/or referral networks, with a multidisciplinary team including expert pathologists, radiologists, dedicated surgeons, radiation oncologists with access to hadron facilities, medical oncologists and a palliative care team.

Local staging should be carried out by MRI. Chordoma should be differentiated from benign notochordal cell tumours, benign lesions with peculiar radiological features believed to be chordoma precursors [112]. If radiological appearance is typical for benign notochordal cell tumours, biopsy is not recommended unless the lesion changes over time. For chordoma, preoperative core-needle biopsy is recommended and the biopsy track needs to be included in the surgical resection. For skull base chordoma, preoperative biopsy is not recommended if the tumour cannot be reached easily or safely, or if there is a high risk of tumour cell seeding [V, C] [113].

*En bloc* R0 resection is the recommended treatment, when feasible and sequelae are accepted by the patient [IV, B]. The expected 5-year recurrence-free survival is > 50%. For sacral chordoma, surgery should definitely be offered as a first choice in case of lesions arising from S4 (sacral spinal nerve 4) and below. It should always be discussed in the context of other alternatives for tumours originating above S3 (sacral spinal nerve 3), given the neurological sequelae associated to surgical resection. For skull base and upper cervical tract chordoma, R0 resection can rarely be done. R1 (microscopic positive margin) should be the goal of surgery in these cases [V, B]. Adjuvant RT should always be considered for skull base and cervical spine chordomas, and for sacral and mobile spine chordoma if R1-resected chordoma is observed in the final pathological examination.

If *en bloc* R0 resection is not feasible, the patient is inoperable or surgical sequelae are not accepted by the patient, definitive RT
Follow-up, long-term implications and survivorship

Follow-up is designed to detect either local recurrence or metastatic disease at a time when early treatment is still possible and might be effective. Follow-up of high-grade tumours should include both a physical examination of the tumour site and assessment of the function and possible complications of any reconstruction. Local imaging and chest X-ray/CT could be a proposed strategy. Strict rules cannot be provided in the absence of any formal prospective studies, and in the context of differing opinions in this panel of experts. A recommended follow-up policy may foresee intervals between checks after the completion of ChT, approximately every 3 months for the first 2 years; every 6 months for years 3–5; every 6–12 months for years 5–10, and thereafter every 0.5–2 years according to local practice and other factors. Chest CT, if used instead of chest X-rays, should be carried out with low-dose, radiation-sparing techniques, particularly in younger patients who will have a higher lifetime risk to experience second, radiation induced malignancies.

In the case of low-grade bone sarcoma, the frequency of follow-up visits may be lower (e.g. 6 months for 2 years and then annually). Late metastases as well as local recurrences and functional deficits may occur >10 years after diagnosis and there is no universally accepted stopping point for tumour surveillance.

In ES, where osseous metastases are likely, isotope bone scanning can be used in addition to X-ray imaging but should be weighed against the additional radiation exposure, particularly in younger patients. More modern techniques (e.g. PET or whole-body MRI) are increasingly being adopted into routine practice but require further evaluation in clinical trials. This is a general priority for all cancers.

There is a lack of consensus among experts about optimal follow-up policies, taking into consideration the specific risk and performance of systematic imaging follow-up regarding the median and long-term risk of second cancers. Some panelists propose 6-monthly follow-up, whereas others suggest 3-month intervals. Some propose interruption of systematic follow-up at 5 years, while others maintain it beyond 10 years. National guidelines may also be different across countries [120]. The lack of consensus and the very limited number of prospective trials point to the need to generate prospective clinical trials on this topic in the future.

It is important to evaluate the long-term toxic effects of ChT, surgery and RT for cured patients, given the incidence of late complications. Monitoring for late effects should be continued for >10 years after treatment, depending on the ChT protocol and radiation used and in conjunction with late effects services when available. Long-term cardiac evaluation is of major importance since it has been shown that deterioration of cardiac function can still occur decades after anthracycline treatment [120–122].

Secondary cancers may arise in survivors of bone sarcomas, either related to, or independent of, irradiation. Secondary leukaemia, particularly acute myeloid leukaemia, may rarely be observed following ChT, as early as 2–5 years after treatment. Developments in genetic understanding of bone sarcoma point to the importance of obtaining a detailed family history and of genetic evaluation in high-risk families. Patients with cancer predisposition syndromes (e.g. Li–Fraumeni or Rothmund–Thomson syndromes) require special care and follow-up.

Methodology

These Clinical Practice Guidelines have been produced by ESMO in partnership with EURACAN, the European Reference Network for rare adult solid cancers. These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development (http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology). They are conceived to provide the standard approach to diagnosis, treatment and survivorship on sarcomas, GISTs and bone sarcomas. Recommended interventions are intended to correspond to the ‘standard’ approaches, according to current consensus among the European multidisciplinary sarcoma community of experts. These are represented by the members of the ESMO Sarcoma Faculty and experts appointed by PaedCan and all institutions belonging to the Sarcoma domain of EURACAN.

Experimental interventions considered to be beneficial are labelled as ‘investigational’. Other non-standard approaches may be proposed to the single patient as ‘options’ for a shared patient physician decision in conditions of uncertainty, as long as some supporting evidence (though not conclusive) is available. Algorithms accompany the text, covering the main typical presentations of disease, and are meant to guide the user throughout the text. The relevant literature has been selected by the expert authors. A summary of recommendations is shown in Table 2. Levels of
Doxorubicin and ifosfamide may prove active in CS, especially in high-grade lesions, and gemcitabine in combination with docetaxel has also been reported.

Skull base CSs can be treated with high-dose RT including proton or carbon ion beam RT.

Dedifferentiated CS is often treated as a high-grade bone sarcoma, with systemic and local therapies that need to be adapted to patient’s age.

Mesenchymal CS is usually considered to be sensitive to adjuvant or neoadjuvant therapy and is treated using an Ewing-type ChT regimen.

Doxorubicin and ifosfamide may prove active in CS, especially in high-grade lesions, and gemcitabine in combination with docetaxel has also been reported to be effective.
Secondary cancers may arise in survivors of bone sarcomas, either related to, or independent of, irradiation. Secondary leukaemia, particularly acute myeloid leukaemia, may rarely be observed following ChT, as early as 2–5 years after treatment.

Follow-up, long-term implications and survivorship

Follow-up of high-grade tumours should include both a physical examination of the tumour site and assessment of the function and possible complications of any reconstruction. Local imaging and chest X-ray/CT could be a proposed strategy.

A recommended follow-up policy varies among experts and may foresee intervals between checks after the completion of ChT, approximately every 3 months for the first 2 years; every 6 months for years 3–5; every 6–12 months for years 5–10, and thereafter every 0.5–2 years. Chest CT, if used instead of chest X-rays, should be carried out with low-dose, radiation-sparing techniques.

For low-grade bone sarcoma, the frequency of follow-up visits may be lower (e.g. 6 months for 2 years and then annually).

In ES, where osseous metastases are likely, isotopic bone scanning can be used in addition to X-ray imaging but should be weighed against the additional radiation exposure.

More modern techniques (e.g. PET or whole-body MRI) are increasingly being adopted into routine practice but require further evaluation in clinical trials.

Long-term toxic effects of ChT, surgery and RT should be evaluated, and monitoring for late effects should be continued for >10 years after treatment, depending on the ChT protocol and radiation used.

Long-term cardiac evaluation is important, as it has been shown that deterioration of cardiac function can still occur decades after anthracycline treatment.

Secondary cancers may arise in survivors of bone sarcomas, either related to, or independent of, irradiation. Secondary leukaemia, particularly acute myeloid leukaemia, may rarely be observed following ChT, as early as 2–5 years after treatment.

AP, alkaline phosphatase; BuMel, busulfan and melphalan; ChT, chemotherapy; CS, chondrosarcoma; CT, computed tomography; ES, Ewing sarcoma; GCT, giant cell tumour; HD-MTX, high-dose methotrexate; LDH, lactate dehydrogenase; MR, magnetic resonance imaging; OS, osteosarcoma; PET, positron emission tomography; R0, no tumour at the margin; R1, microscopic tumour at the margin; RT, radiotherapy; S2-S4, sacral spinal nerve 2-4; WHO, World Health Organization.
Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sohi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Dompé, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotixi, honoraria from Novartis, Lilly, PharmaMar and Nanobiotixi, and research funds from PharmaMar and travel grants from PharmaMar and Nanobiotixi; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE Healthcare and Philips and has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotixi and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daiichi, Deciphera, ImmuneDesign, Lilly, Merck and PharmaMar; JI has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported research sponsored by Novartis, Pfizer, Bayer, Lilly, Novartis and PharmaMar, advisory role for Bayer and Lilly and travel grants from PharmaMar; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; IL has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis and Pfizer for scientific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar and Lilly; PRu has received honoraria for lectures from Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and has served as a member of advisory board for Novartis, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint Medicines; PS has received honoraria from Daiichi Sankyo Pharma, Eisai, Eli Lilly, Medspace, Novartis, Swedish Orphan Biovitrum, has reported consulting or advising roles for Sixth Element Capital, Adaptimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boeringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, Ipsi, Lexo Oncology, Medspace, Nektar, Novartis, Philogen, Piqu Therapeutics, Plexxikon, is a member of speaker’s bureau of Bayer, Eisai, Eli Lilly, GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan Biovitrum, has received research grants from Bayer, Blueprint Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis, Plexxikon, and has received travel grants from Sixth Element Capital, Adaptimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, GlaxoSmithKline, Ipsi, Lexo Oncology, Medspace, Nektar, Novartis, PharmaMar, Philogen, Piqu Therapeutics, Plexxikon, Swedish Orphan Biovitrum; SSt has received honoraria from Eli Lilly and PharmaMar, research grants from Amgen Dompé, Advencehen, Bayer, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Novartis, Pfizer and PharmaMar; travel grants from PharmaMar and has reported advisory/consultant roles for Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar; WVdG has received research grants from Novartis; EW has reported travel/research grants and/or honoraria from Novartis Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotixi and Bayer; JYB has declared research grants and honoraria from Novartis, GlaxoSmithKline, Pfizer and Bayer; NA, RB, BB, LB, AB, CD, FF, AFe, VF, AFer, NG, TG, RLH, SHN, RI, SK, LK, DAK, RL, OM, MM, BM, RP, PP, SP-N, ALP, MHR, AAS, SSI.

Table 3. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System*)

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Grades of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
<tr>
<td>II</td>
<td>B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended</td>
</tr>
<tr>
<td>III</td>
<td>C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, …), optional</td>
</tr>
<tr>
<td>IV</td>
<td>D Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
</tr>
<tr>
<td>V</td>
<td>E Strong evidence against efficacy or for adverse outcome, never recommended</td>
</tr>
</tbody>
</table>

*By permission of the Infectious Diseases Society of America [123].
References


